# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in ...
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Neutral and raises the price target from $220 to $225.
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.
JMP Securities analyst David Turkaly reiterates Steris (NYSE:STE) with a Market Outperform and maintains $265 price target.
Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 m...
STERIS today is also announcing a targeted restructuring plan, which includes restructuring of the Healthcare surgical business...
Steris (NYSE:STE) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $2.35 by 9.79 per...
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.